Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients

P. Vici, G. Viola, C. Botti, S. Rossi, C. Vitucci, S. Corsetti, L. Di Lauro, D. Sergi, P. Foggi, P. Perri, C. Tirelli, M. Mottolese, S. I S Fattoruso, M. Lopez

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Considering the clinical benefit of trastuzumab in advanced breast cancer, five prospective adjuvant randomized trials have recently been completed and early results have been published. Two of them, (NSABP-B31 and NCCTG N9831), employed anthracy- cline-containing regimens with sequential paclitaxel, with or without trastuzumab. The third study, HERA trial, randomized patients after adjuvant chemotherapy into an observational arm, one or two years of trastuzumab. Results of these studies, after a median follow up of 2-3 years confirm a DFS and OS benefit for the experimental arms. The worst rate of cardiotoxicity, in terms of incidence of CHF, with the use of trastuzumab and anthracycline based regimens was 4.1% in the trastuzumab arm of the NSABP-B31 trial. Among the five trastuzumab trials, two, BCIRG 006 and FinHer, employed docetaxel-based regimens. The innovative BCIRG 006 trial compared AC→docetaxel (T) with two trastuzumab-containing regimens, AC→TH, and a non-anthracycline-containing regimens, TCH, with a clear advantage in DFS for both trastuzumab arms. Data from the second interim analysis indicate that, in the subgroup of patients without co-amplification of topoisomerase 2 (TOPO-2), the arm without trastuzumab (AC→T) showed a DFS significantly poorer that in the other arms; moreover, if we consider the lower toxicity of TCH regimen in comparison with anthracycline-containing arms, the innovative statements offered by BCIRG 006 trial appear evident, and these findings opened an important question about the consolidated employment of anthracyclines in adjuvant setting. The FinHer trial was a small trial testing a short course of trastuzumab (9 weeks) concomitantly with a chemotherapy including docetaxel, and there was a significant advantage in DFS for the trastuzumab based arms, without relevant toxicity and without any cardiotoxicity. Although data from all trastuzumab adjuvant trials, and without particulary from BCIRG-006 and FinHer trials, appear very intriguing, further follow-up is required.

Original languageEnglish
Pages (from-to)449-452
Number of pages4
JournalClinica Terapeutica
Volume159
Issue number6
Publication statusPublished - Nov 2008

Fingerprint

docetaxel
Breast Neoplasms
Anthracyclines
Therapeutics
Trastuzumab

Keywords

  • Breast cancer
  • Docetaxel
  • HER2 positive
  • Taxanes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Vici, P., Viola, G., Botti, C., Rossi, S., Vitucci, C., Corsetti, S., ... Lopez, M. (2008). Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients. Clinica Terapeutica, 159(6), 449-452.

Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients. / Vici, P.; Viola, G.; Botti, C.; Rossi, S.; Vitucci, C.; Corsetti, S.; Di Lauro, L.; Sergi, D.; Foggi, P.; Perri, P.; Tirelli, C.; Mottolese, M.; Fattoruso, S. I S; Lopez, M.

In: Clinica Terapeutica, Vol. 159, No. 6, 11.2008, p. 449-452.

Research output: Contribution to journalArticle

Vici, P, Viola, G, Botti, C, Rossi, S, Vitucci, C, Corsetti, S, Di Lauro, L, Sergi, D, Foggi, P, Perri, P, Tirelli, C, Mottolese, M, Fattoruso, SIS & Lopez, M 2008, 'Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients', Clinica Terapeutica, vol. 159, no. 6, pp. 449-452.
Vici P, Viola G, Botti C, Rossi S, Vitucci C, Corsetti S et al. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients. Clinica Terapeutica. 2008 Nov;159(6):449-452.
Vici, P. ; Viola, G. ; Botti, C. ; Rossi, S. ; Vitucci, C. ; Corsetti, S. ; Di Lauro, L. ; Sergi, D. ; Foggi, P. ; Perri, P. ; Tirelli, C. ; Mottolese, M. ; Fattoruso, S. I S ; Lopez, M. / Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients. In: Clinica Terapeutica. 2008 ; Vol. 159, No. 6. pp. 449-452.
@article{3ab5445080344403ac51bef123313793,
title = "Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients",
abstract = "Considering the clinical benefit of trastuzumab in advanced breast cancer, five prospective adjuvant randomized trials have recently been completed and early results have been published. Two of them, (NSABP-B31 and NCCTG N9831), employed anthracy- cline-containing regimens with sequential paclitaxel, with or without trastuzumab. The third study, HERA trial, randomized patients after adjuvant chemotherapy into an observational arm, one or two years of trastuzumab. Results of these studies, after a median follow up of 2-3 years confirm a DFS and OS benefit for the experimental arms. The worst rate of cardiotoxicity, in terms of incidence of CHF, with the use of trastuzumab and anthracycline based regimens was 4.1{\%} in the trastuzumab arm of the NSABP-B31 trial. Among the five trastuzumab trials, two, BCIRG 006 and FinHer, employed docetaxel-based regimens. The innovative BCIRG 006 trial compared AC→docetaxel (T) with two trastuzumab-containing regimens, AC→TH, and a non-anthracycline-containing regimens, TCH, with a clear advantage in DFS for both trastuzumab arms. Data from the second interim analysis indicate that, in the subgroup of patients without co-amplification of topoisomerase 2 (TOPO-2), the arm without trastuzumab (AC→T) showed a DFS significantly poorer that in the other arms; moreover, if we consider the lower toxicity of TCH regimen in comparison with anthracycline-containing arms, the innovative statements offered by BCIRG 006 trial appear evident, and these findings opened an important question about the consolidated employment of anthracyclines in adjuvant setting. The FinHer trial was a small trial testing a short course of trastuzumab (9 weeks) concomitantly with a chemotherapy including docetaxel, and there was a significant advantage in DFS for the trastuzumab based arms, without relevant toxicity and without any cardiotoxicity. Although data from all trastuzumab adjuvant trials, and without particulary from BCIRG-006 and FinHer trials, appear very intriguing, further follow-up is required.",
keywords = "Breast cancer, Docetaxel, HER2 positive, Taxanes",
author = "P. Vici and G. Viola and C. Botti and S. Rossi and C. Vitucci and S. Corsetti and {Di Lauro}, L. and D. Sergi and P. Foggi and P. Perri and C. Tirelli and M. Mottolese and Fattoruso, {S. I S} and M. Lopez",
year = "2008",
month = "11",
language = "English",
volume = "159",
pages = "449--452",
journal = "Clinica Terapeutica",
issn = "0009-9074",
publisher = "Societa Editrice Universo",
number = "6",

}

TY - JOUR

T1 - Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients

AU - Vici, P.

AU - Viola, G.

AU - Botti, C.

AU - Rossi, S.

AU - Vitucci, C.

AU - Corsetti, S.

AU - Di Lauro, L.

AU - Sergi, D.

AU - Foggi, P.

AU - Perri, P.

AU - Tirelli, C.

AU - Mottolese, M.

AU - Fattoruso, S. I S

AU - Lopez, M.

PY - 2008/11

Y1 - 2008/11

N2 - Considering the clinical benefit of trastuzumab in advanced breast cancer, five prospective adjuvant randomized trials have recently been completed and early results have been published. Two of them, (NSABP-B31 and NCCTG N9831), employed anthracy- cline-containing regimens with sequential paclitaxel, with or without trastuzumab. The third study, HERA trial, randomized patients after adjuvant chemotherapy into an observational arm, one or two years of trastuzumab. Results of these studies, after a median follow up of 2-3 years confirm a DFS and OS benefit for the experimental arms. The worst rate of cardiotoxicity, in terms of incidence of CHF, with the use of trastuzumab and anthracycline based regimens was 4.1% in the trastuzumab arm of the NSABP-B31 trial. Among the five trastuzumab trials, two, BCIRG 006 and FinHer, employed docetaxel-based regimens. The innovative BCIRG 006 trial compared AC→docetaxel (T) with two trastuzumab-containing regimens, AC→TH, and a non-anthracycline-containing regimens, TCH, with a clear advantage in DFS for both trastuzumab arms. Data from the second interim analysis indicate that, in the subgroup of patients without co-amplification of topoisomerase 2 (TOPO-2), the arm without trastuzumab (AC→T) showed a DFS significantly poorer that in the other arms; moreover, if we consider the lower toxicity of TCH regimen in comparison with anthracycline-containing arms, the innovative statements offered by BCIRG 006 trial appear evident, and these findings opened an important question about the consolidated employment of anthracyclines in adjuvant setting. The FinHer trial was a small trial testing a short course of trastuzumab (9 weeks) concomitantly with a chemotherapy including docetaxel, and there was a significant advantage in DFS for the trastuzumab based arms, without relevant toxicity and without any cardiotoxicity. Although data from all trastuzumab adjuvant trials, and without particulary from BCIRG-006 and FinHer trials, appear very intriguing, further follow-up is required.

AB - Considering the clinical benefit of trastuzumab in advanced breast cancer, five prospective adjuvant randomized trials have recently been completed and early results have been published. Two of them, (NSABP-B31 and NCCTG N9831), employed anthracy- cline-containing regimens with sequential paclitaxel, with or without trastuzumab. The third study, HERA trial, randomized patients after adjuvant chemotherapy into an observational arm, one or two years of trastuzumab. Results of these studies, after a median follow up of 2-3 years confirm a DFS and OS benefit for the experimental arms. The worst rate of cardiotoxicity, in terms of incidence of CHF, with the use of trastuzumab and anthracycline based regimens was 4.1% in the trastuzumab arm of the NSABP-B31 trial. Among the five trastuzumab trials, two, BCIRG 006 and FinHer, employed docetaxel-based regimens. The innovative BCIRG 006 trial compared AC→docetaxel (T) with two trastuzumab-containing regimens, AC→TH, and a non-anthracycline-containing regimens, TCH, with a clear advantage in DFS for both trastuzumab arms. Data from the second interim analysis indicate that, in the subgroup of patients without co-amplification of topoisomerase 2 (TOPO-2), the arm without trastuzumab (AC→T) showed a DFS significantly poorer that in the other arms; moreover, if we consider the lower toxicity of TCH regimen in comparison with anthracycline-containing arms, the innovative statements offered by BCIRG 006 trial appear evident, and these findings opened an important question about the consolidated employment of anthracyclines in adjuvant setting. The FinHer trial was a small trial testing a short course of trastuzumab (9 weeks) concomitantly with a chemotherapy including docetaxel, and there was a significant advantage in DFS for the trastuzumab based arms, without relevant toxicity and without any cardiotoxicity. Although data from all trastuzumab adjuvant trials, and without particulary from BCIRG-006 and FinHer trials, appear very intriguing, further follow-up is required.

KW - Breast cancer

KW - Docetaxel

KW - HER2 positive

KW - Taxanes

UR - http://www.scopus.com/inward/record.url?scp=58849094563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58849094563&partnerID=8YFLogxK

M3 - Article

C2 - 19169607

AN - SCOPUS:58849094563

VL - 159

SP - 449

EP - 452

JO - Clinica Terapeutica

JF - Clinica Terapeutica

SN - 0009-9074

IS - 6

ER -